Cytrx Corp., of Los Angeles, said updated data from an ongoing open-label phase II trial of aldoxorubicin for the treatment of unresectable glioblastoma multiforme (GBM) suggests that by binding to albumin, aldoxorubicin may allow doxorubicin to cross the blood-brain barrier and into the malignancy.